nab-paclitaxel,cyclophosphamide
immunitybio
[]
 doubles historical overall survival rate of 3rd line or greater #pancreaticcancer patients with novel combo therapy #ascogi #gi23 $ibrx #biotechnology 
#Commodities #Uranium #Biotech | Subscribe to my free blog: https://t.co/gwiArtu8D6 | My #wikifolio fund trades on German Stock Exchange https://t.co/XYVdA7iyxL 📈